In clinics, ERBB2 target therapies by monoclonal antibodies or tyrosine kinase inhibitors are the gold standard to treat ERBB2-overexpressing (HER2+) breast cancer patients [reviewed in (1)]. This evidence concerns the gene ERBB2 and breast cancer.